Biogen cuts FY profit forecast on acquisition charges, Q1 beat offers mixed signal

What happened

Biogen reduced its full-year profit forecast on Wednesday, citing acquisition-related charges, even as first-quarter earnings surpassed expectations on stronger sales of Alzheimer's drug Leqembi and newer rare-disease treatments. The guidance cut echoes a pattern seen in prior quarters, where business-development costs repeatedly pressure reported EPS despite underlying revenue stability. Launch products and rare-disease growth continue to offset multiple sclerosis erosion, but the incremental charges highlight management's willingness to trade near-term earnings for pipeline expansion. The stock's reaction will likely hinge on whether investors focus on the Q1 beat and Leqembi momentum or the lowered outlook and ongoing EPS volatility. This mixed signal reinforces the existing wait-and-see posture until clearer 2026 guidance emerges.

Implication

Investors should view this as a continuation of Biogen's pattern: operational beats offset by acquisition-related charges, keeping reported EPS unpredictable. The Q1 beat on Leqembi and rare-disease sales confirms that portfolio transition is progressing, but the guidance cut underscores that business development remains a drag on earnings visibility. At ~16.8x trailing EPS, the stock already prices in stabilization, leaving limited upside unless 2026 guidance shows clear top-line growth. Wait for the full-year 2025 results and initial 2026 outlook to assess whether launch momentum can sustainably offset MS declines and BD charges. The attractive entry remains near $165, and any dip toward that level could offer a better risk-reward, but current valuation offers no compelling margin of safety.

Thesis delta

The news adds another instance of operational strength being masked by BD-related earnings cuts, reinforcing the existing wait thesis. The Q1 beat on Leqembi and rare-disease growth is encouraging but insufficient to change the call without evidence of sustained top-line acceleration. The pattern of guidance cuts, even on better underlying trends, keeps conviction at moderate and favors waiting for 2026 guidance to confirm a growth inflection.